Data on a chemical's mechanisms of action can be critical to decisions in human health risk assessment, especially regarding potential differences in sensitivity to adverse effects across and within species. U.S. Environmental Protection Agency (EPA) guidelines for carcinogen risk assessment ([@b98-ehp-117-1664]) particularly emphasize the use of mechanistic data to inform the evaluation of the mode of action (MOA) of a chemical. These guidelines define MOA as "a sequence of key events and processes, starting with interaction of an agent with a cell, proceeding through operational and anatomical changes and resulting in cancer formation." A "key event" is an empirically observable precursor step that is itself a necessary element of the MOA or is a biologically based marker for such an element. Mode is distinguished from mechanism, with the latter implying the complete series of events that lead from exposure to disease. It is recognized that the precise carcinogenic mechanism(s) is unknown for essentially all chemicals, and the MOA concept attempts to address this knowledge deficit by focusing on key steps required (i.e., necessary) for the carcinogenic process.

One of the most challenging determinations in evaluating mechanistic data is whether an identified MOA is the cause of cancer (or another adverse health outcome). As recently reviewed ([@b34-ehp-117-1664]), the U.S. EPA and other MOA approaches have adopted the [@b39-ehp-117-1664] considerations to evaluate hypothesized MOAs. However, the Hill considerations were not developed for this purpose. They were instead designed to assist epidemiologists in making inductive inferences about the causal relationship of observed associations or, in the language of chemical carcinogenesis, as an aid in addressing the question, "Does a chemical exposure cause cancer?" Causal inference is often used in epidemiology because direct experimentation is generally not feasible; in contrast, MOA questions---for example, "How does a chemical cause cancer?"---are almost entirely addressed through empirical tests of the pertinent hypotheses in laboratory studies. Although some of the Hill considerations (e.g., temporality and dose--response relationships) may be helpful in ruling out implausible MOAs, their general utility for elucidating if biological effects that may be similarly related to exposure (e.g., cytotoxicity) are actual "key events" in the causal pathway(s) to cancer deserves scrutiny. It is unclear whether they can distinguish effects that are merely associated with cancer (by virtue of a common causal connection with the exposure) from effects that are causally linked as part of an MOA for carcinogenesis. Moreover, even when particular effects are key events in a causal pathway to cancer, the Hill considerations cannot rule out the causal contribution of other effects or pathways. In order to address these types of inquiry, direct experimentation is needed, and MOA hypotheses should be empirically challenged using experimental studies, in accordance with the scientific method.

Another difficult aspect of mechanistic data evaluation is the assessment of likely human sensitivity to an identified laboratory animal MOA. The [@b98-ehp-117-1664] guidelines address this issue separately during the hazard characterization and dose--response components of risk assessment, as well as in the identification of susceptible populations. This approach avoids conflating qualitative and quantitative issues during hazard characterization, and thereby prevents human relevance from being ruled out based on differences in sensitivity across species. Instead, information suggesting quantitative differences is "flagged for consideration in the dose--response assessment" and quantitative adjustments may also be made based on identified susceptibilities (e.g., life stage). However, a limitation of this approach and of MOA approaches in general is the tacit assumption of site concordance, which departs from the basic tenet of U.S. EPA cancer risk assessment that site concordance across species is not required in hazard evaluation, a tenet consistent with observations of site disconcordance across countless rodent bioassays.

We explore these aspects of MOA evaluation in consideration of peroxisome proliferator--activated receptor-α (PPAR-α) activation as an MOA for rodent liver tumor carcinogenesis. This MOA has been invoked to support the conclusion that environmental contaminants \[e.g., the plasticizer di(2-ethylhexyl) phthalate (DEHP)\] would lack carcinogenic risk in humans. For instance, the International Agency for Research on Cancer (IARC) downgraded the classification of DEHP from "possibly carcinogenic to humans" to "not classifiable" based on an expert panel's acceptance of the hypothesis that DEHP induces liver tumors in rodents by a mechanism dependent on PPAR-α activation that is not relevant to humans ([@b45-ehp-117-1664]). The use of evidence of the PPAR-α activation MOA to dismiss the human relevance of effects observed in laboratory animals has been questioned (e.g., [@b6-ehp-117-1664]; [@b63-ehp-117-1664]) based on the lack of experimental studies empirically challenging the MOA hypothesis.

Two recent studies have provided evidence that DEHP induces liver tumors in PPAR-α--null mice ([@b47-ehp-117-1664]) and that hepatocyte PPAR-α activation (and its sequelae) in a transgenic mouse model is insufficient to evoke hepatocarcinogenesis ([@b106-ehp-117-1664]). These data provide motivation for the present reexamination of the evidential support for the proposed PPAR-α activation MOA hypothesis as a basis for assessing human health risks of DEHP and other environmental contaminants that activate PPAR-α. Although we focus on the human health risk assessment implications of recent data rather than comprehensively reviewing the topic area, our analyses also encompass some prior studies reviewed more extensively elsewhere ([@b1-ehp-117-1664]; [@b54-ehp-117-1664]; [@b63-ehp-117-1664]). Particularly, we examine the extent to which the quantitative relationship between the proposed key events and liver tumorigenesis in rodents, as well as the relative human sensitivity to the hypothesized rodent MOA, have been characterized. In addition, we consider whether the available epidemiologic evidence on fibrates affords a test of the supposition that laboratory animal data about PPAR-α agonists indicate the absence of human health risks. We conclude with a discussion of alternative approaches to analyses of mechanistic information for chemicals of environmental concern that could be considered to address some of the challenges elaborated herein.

Is PPAR-α Activation Essential for DEHP Liver Carcinogenesis?
=============================================================

[Figure 1A](#f1-ehp-117-1664){ref-type="fig"} shows a widely cited version of the hypothesized MOA for hepatocarcinogenesis induced by PPAR-α agonists, posited by [@b54-ehp-117-1664], in which three key causal events were proposed: activation of the receptor, perturbation of hepatocellular apoptosis and proliferation, and selective clonal expansion. [@b54-ehp-117-1664] concluded that PPAR-α activation represents a key event in the liver tumor MOA for DEHP. The evidential support included the *in vitro* demonstration of receptor activation by its monoester metabolite \[mono-2-ethylhexyl phthalate (MEHP)\] ([@b46-ehp-117-1664]; [@b59-ehp-117-1664]). In addition, peroxisome proliferation (or increased peroxisomal enzyme activity), an associative event in the MOA, was induced by tumorigenic doses of DEHP in the liver of mice and rats or by MEHP in rat hepatocytes ([@b15-ehp-117-1664]; [@b31-ehp-117-1664], [@b32-ehp-117-1664]; [@b38-ehp-117-1664]; [@b65-ehp-117-1664], [@b66-ehp-117-1664]; [@b79-ehp-117-1664]). Comparable to the results found for prototypical agonist \[4-chloro-6-(2,3-xylidino)-2-pyrimidyl-thio\]acetic acid (Wy-14,643), DEHP failed to induce peroxisomal enzymes and peroxisome proliferation in PPAR-α--null mice with 24 weeks of exposure ([@b102-ehp-117-1664]). This finding supported a causal role for receptor activation in peroxisome proliferation, but a study of the subsequent development of tumors by DEHP in PPAR-α--null mice had not been conducted. However, [@b74-ehp-117-1664] had previously reported the absence of tumors in nine PPAR-α--null mice exposed to Wy-14,643 at 11 months, whereas each of the six similarly exposed wild-type mice had multiple hepatocellular neoplasms. Based on this 11-month tumor bioassay of Wy-14,643 ([@b74-ehp-117-1664]) and the short-term DEHP study ([@b102-ehp-117-1664]) in PPAR-α--null mice, it was assumed that "a long-term study of DEHP using PPAR-α--null mice would provide the same results" ([@b54-ehp-117-1664]). This assumption in turn supported the conclusion that "all the effects observed are due only to the activation of this receptor and the downstream events resulting from this activation and that no other modes of action are operant" ([@b54-ehp-117-1664]).

Recent studies have experimentally challenged both the assumption of a lack of carcinogenicity in a long-term DEHP bioassay in PPAR-α--null mice and the hypothesis that PPAR-α activation is the sole operant MOA for hepatocarcinogenesis. In a 2-year bioassay, [@b47-ehp-117-1664] found that DEHP (100 or 500 ppm) induces liver tumors in PPAR-α--null mice and they also reported a significant trend for the observed increase in total liver tumors with DEHP in PPAR-α--null male mice with Sv129 genetic background generated as described in [@b57-ehp-117-1664]. For the present report, we performed additional statistical analyses to compare the [@b47-ehp-117-1664] results with those of a prior DEHP bioassay in B6C3F1 wild-type mice ([@b15-ehp-117-1664]). A pairwise analysis showed that DEHP (500 ppm) significantly increased adenomas in PPAR-α--null mice but not in companion wild-type mice compared with their respective controls ([Figure 2](#f2-ehp-117-1664){ref-type="fig"}). In the David et al. study of B6C3F1 mice, DEHP (500 ppm) also significantly increased adenomas and adenomas plus carcinomas ([Figure 2](#f2-ehp-117-1664){ref-type="fig"}). Moreover, we found a significant dose--response trend for adenomas and for adenomas plus carcinomas in both the Ito et al. PPAR-α--null mice and the David et al. B6C3F1 mice after exposure to DEHP ([Figure 2](#f2-ehp-117-1664){ref-type="fig"}). Additionally, we found no statistically significant differences between groups at the same dose, including controls, consistent with mouse strain and PPAR-α genotype having no influence on carcinogenicity under the study conditions.

The observed lack of difference in reported control incidences across groups lends support to our approach of basing comparative analyses on concurrent controls. Historical data on spontaneous liver tumor incidences in PPAR-α--null mice are limited; [@b47-ehp-117-1664] is the largest published 2-year bioassay in PPAR-α--null mice, reporting findings for 24 of 25 surviving unexposed animals at 23 months of age. A different laboratory that had established a distinct breeding colony reported mouse liver tumor incidences in 12 PPAR-α--null Sv129/C57BL/6 mice approximately 2 years of age ([@b42-ehp-117-1664]). Adenomas and carcinomas were reported in 6 of 12 and 2 of 12 PPAR-α--null mice, respectively, compared with adenomas in 5 of 22 wild-type animals. As Howroyd et al. noted, "The relatively small number of animals available made it difficult to draw robust conclusions concerning enhancement of spontaneous findings in PPARα-null mice." In addition, the low survival of Howroyd et al.'s PPAR-α--null mice relative to those of [@b47-ehp-117-1664] limit statistical comparisons based on this data set.

In sum, the [@b47-ehp-117-1664] study is consistent with the view that DEHP carcinogenesis can occur independently of PPAR-α activation. As noted in a report by the [@b69-ehp-117-1664], this finding "calls into question" the IARC conclusions regarding the carcinogenic risks of DEHP ([@b45-ehp-117-1664]). Indeed, as summarized in [Figure 1B](#f1-ehp-117-1664){ref-type="fig"}, PPAR-α activation and the subsequent key events in the hypothesized MOA do not appear to represent the sole cause of DEHP liver tumorigenesis. Although new hypotheses are being generated based on more detailed comparisons between wild-type and PPAR-α--null mice ([@b47-ehp-117-1664]; [@b93-ehp-117-1664]), the mechanisms by which DEHP induces hepatocarcinogenesis remain unknown.

Do PPAR-α Activation and Its Sequelae in Hepatocytes Cause Cancer?
==================================================================

A second recent study raises further questions regarding whether PPAR-α activation in hepatocytes is causally linked to hepatocarcinogenesis as a sole operant MOA ([@b106-ehp-117-1664]). The experimental approach entailed fusing the mouse PPAR-α to the potent viral transcriptional activator VP16 under control of the liver-enriched activator protein (LAP) promoter, resulting in targeted constitutive expression of activated PPAR-α in hepatocytes. In LAP-VP16PPAR-α transgenic mice, many of the same hepatic responses (in type and magnitude) were seen as with PPAR-α ligand treatment of companion wild-type Sv129 mice. For instance, DNA synthesis was increased in LAP-VP16PPAR-α transgenic mice; the effect was persistent and still evident at 11 months of age. In addition, increases were reported in markers of peroxisome proliferation \[including increases in expression of peroxisomal membrane protein 70, acyl coenzyme A (CoA) oxidase and cytochrome P4A (CYP4A) family genes, and enhanced cyanide-insensitive palmitoyl CoA oxidation\]. Other effects included an increase in cell-cycle genes (cyclin D1 and cyclin-dependent kinase-1 and -4) and a decrease in serum triglycerides and free fatty acids. Together, the results from this transgenic model are consistent with the view that PPAR-α activation and its sequelae are alone sufficient to induce increased hepatocyte DNA synthesis (a key event in the hypothesized MOA) as well as peroxisome proliferation.

However, constitutive PPAR-α activation in hepatocytes in the LAP-VP16PPAR-α transgenic mouse model was not sufficient to induce several important hepatic responses stimulated by PPAR-α ligand treatment of wild-type mice. Notably, [@b106-ehp-117-1664] found no preneoplastic hepatic lesions or hepatocellular neoplasia in "\> 20 LAP-VP16PPAR-α mice at the age of \< 1 year." In sharp contrast, wild-type mice exposed to the PPAR-α agonist Wy-14,643 for 11 months developed grossly visible lesions consistent with previous reports of its hepatocarcinogenicity (e.g., [@b74-ehp-117-1664]). Interestingly, nonparenchymal cell proliferation was seen with Wy-14,643 exposure of wild-type mice but was absent in the LAP-VP16PPAR-α transgenic mice. In addition, although liver weight was increased in LAP-VP16PPAR-α transgenic mice, the extent of hepatomegaly was reduced compared with Wy-14,643--exposed wild-type mice, and hepatocellular hypertrophy was absent.

Thus, the [@b106-ehp-117-1664] study provides evidence that, by itself, PPAR-α activation (and its sequelae) is not sufficient to induce hepatocarcinogenesis. These data are therefore inconsistent with the hypothesis that effects mediated through PPAR-α activation constitute a complete MOA for carcinogenesis ([Figure 1C](#f1-ehp-117-1664){ref-type="fig"}). Notably, key events in the proposed MOA such as the robust and sustained elevation in hepatocyte proliferation (evidenced by enhanced DNA synthesis), accompanied by enzyme changes commonly associated with peroxisome proliferation, did not evoke hepatocarcinogenesis. In fact, a comparable extent of sustained increases in hepatocyte DNA synthesis was seen with constitutive PPAR-α activation in the LAP-VP16PPAR-α transgenic mouse model and Wy-14,643 exposure in wild-type mice, but only the latter developed liver tumors under comparable experimental paradigms.

These observations indicate that events besides the prolonged elevation of proliferation (evidenced by an increase in DNA synthesis) are necessary in the carcinogenic MOA for Wy-14,643, a compound frequently used as the model for PPAR-α agonism. Moreover, in contrast to Wy-14,643, DEHP only transiently increases DNA synthesis and at higher doses than required for carcinogenesis ([@b12-ehp-117-1664]; [@b15-ehp-117-1664]; [@b60-ehp-117-1664]) ([Table 1](#t1-ehp-117-1664){ref-type="table"}). Only short-term increases in rat liver DNA synthesis are seen with many other PPAR-α agonists, including clofibrate \[ethyl 2-(4-chlorophenoxy)-2-methylpropanoate\] ([@b94-ehp-117-1664]), clofibric acid \[2-(*p*-chlorophenoxy)-2-methylpropionic acid\] ([@b2-ehp-117-1664]; [@b61-ehp-117-1664]), nafenopin (2-methyl-2\[*p*-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy\]-propionic acid) ([@b19-ehp-117-1664]; [@b56-ehp-117-1664]), ciprofibrate (2-\[4-(2,2-dichlorocyclopropyl)phenoxy\]-2-methylpropanoic acid) ([@b108-ehp-117-1664]), and trichloroacetic acid (TCA) ([@b101-ehp-117-1664]). A causal mechanistic link between transient increases in DNA synthesis and rodent hepatocarcinogenesis remains to be established ([@b64-ehp-117-1664]).

Are key or associative events in the PPAR-α activation MOA quantitatively predictive of hepatocarcinogenicity?
--------------------------------------------------------------------------------------------------------------

Another question to consider is whether potency for PPAR-α activation or its attendant sequelae is quantitatively associated with carcinogenic activity or potency. If so, differences in sensitivity for carcinogenesis (such as may occur across species) could be predicted using quantitative information about the key events alone. However, there are limitations in the dose--response data available for analyses of quantitative relationships between potencies for precursor events in the proposed PPAR-α activation MOA and for liver tumor induction. Most tumor data, including for the best-characterized PPAR-α agonists, are for exposure concentrations inducing well above 50% carcinogenic potency (TD~50~; the daily dose inducing tumors in half of the mice that would otherwise have remained tumor-free) with less-than-lifetime administration. Precursor events have typically been studied at a single dose, often eliciting a near maximal response, thus precluding benchmark-based comparisons across studies. This is especially true for Wy-14,643, which has been administered most often at only one exposure concentration (1,000 ppm) that elicits a 100% tumor incidence after 1 year or less ([@b74-ehp-117-1664]) and that also appears to be necrogenic ([@b105-ehp-117-1664]). On the other hand, hypothesized precursor events such as hepatomegaly, peroxisome proliferation, and increased DNA synthesis appear to have reached their maximal responses at 50 ppm Wy-14,643, with some statistically significant responses at doses as low as 5 ppm ([@b61-ehp-117-1664]; [@b99-ehp-117-1664]). Potencies across compounds have rarely been compared in a single study using the same experimental paradigm. These deficits in the database notwithstanding, we provide below an assessment of the quantitative predictive power of the potency for four proposed data elements for establishing the hypothesized MOA for hepatocarcinogenesis: PPAR-α activation in mice, and hepatomegaly, DNA synthesis, and increased peroxisome proliferation in rats.

PPAR-α activation in mice
-------------------------

[Table 2](#t2-ehp-117-1664){ref-type="table"} presents data for four peroxisome proliferators in order of decreasing potency for inducing mouse liver tumors. We selected these compounds because of their importance to environmental human health risk assessments and because data to derive receptor activation potency indicators were available from a single study ([@b59-ehp-117-1664]). The trans-activation potencies of MEHP, Wy-14,643, dichloroacetic acid (DCA), and TCA for the mouse PPAR-α were monitored using a luciferase reporter gene containing multiple PPAR response elements derived from the rat hydratase/dehydrogenase promoter in transiently transfected COS-1 monkey kidney cells. The derived potency indicators were compared with the TD~50~ from the Carcinogenic Potency Database (CPDB) of [@b29-ehp-117-1664]. Note that for Wy-14,643, the dose listed yielded a maximal response and thus represents an upper limit to the TD~50~ (indicated by "\<"). Two estimates of PPAR-α transactivation potency are given, the first based on the effective concentration yielding 50% of the maximal response (EC~50~) and the second based on the effective concentration required for a 2-fold increase in activity (EC~2-fold~) ([@b59-ehp-117-1664]). Orally administered DEHP undergoes presystemic hydrolysis catalyzed by lipase to MEHP in the gut, with mice exhibiting higher lipase activities in the small intestine compared with rats and marmosets ([@b49-ehp-117-1664]; [@b53-ehp-117-1664]; [@b78-ehp-117-1664]). Therefore, because the mouse liver is likely exposed predominantly to MEHP rather than DEHP and because unmetabolized DEHP does not exhibit PPAR-α activity, the transactivation activity of its metabolite MEHP is given but compared with the hepatocarcinogenic potency indicator for DEHP. No data on the potency for transactivation of rat PPAR-α by chemicals in the CPDB were located to enable a similar comparison in rats.

These data clearly show a lack of correlation between the potencies for *in vitro* PPAR-α transactivation and *in vivo* tumorigenesis across different PPAR-α agonists. Especially notable is that MEHP exhibited orders of magnitude more potency for transactivating mouse PPAR-α than does DCA, but DEHP was 6-fold less potent as a mouse hepatocarcinogen. TCA was more similar in potency to DCA for both outcomes; that is, it was also dramatically less active at transactivating PPAR-α than DEHP despite exhibiting comparable hepatocarcinogenic potency. Wy-14,643 and MEHP activate PPAR-α at comparable concentrations when directly compared in the transactivation assay, but the carcinogenic potency of Wy-14,643 was estimated to be at least 70-fold higher than that of DEHP. This difference cannot be explained by hepatic conversion of DEHP to its monoester MEHP, because studies in rats demonstrate that orally administered DEHP undergoes presystemic hydrolysis to MEHP in the gut ([@b53-ehp-117-1664]; [@b78-ehp-117-1664]). Possible explanations for these results include one or more of the following: *a*) the transactivation assay may not be an accurate quantitative indicator of *in vivo* receptor activation; *b*) the rate and nature of effects downstream of PPAR-α activation may depend on the ligand; or *c*) rate-limiting events independent of PPAR-α activation may contribute to mouse hepatocarcinogenesis by the agonists examined.

Hepatomegaly, DNA synthesis, and peroxisome proliferation in rats
-----------------------------------------------------------------

[Table 1](#t1-ehp-117-1664){ref-type="table"} compares potency indicators for various precursor effects at the TD~50~ for four PPAR-α agonists and rat hepatocarcinogens. Our analysis of whether there are consistent levels of *in vivo* precursor effect induction across peroxisome proliferators at the TD~50~ does not include all of the data from a similar, prior analysis by [@b1-ehp-117-1664], for several reasons. First, unlike the CPDB, Ashby et al. did not adjust carcinogenicity data for less-than-lifetime dosing, which is relevant for most compounds. Second, for those mouse carcinogens reported in the CPDB, only acute data are available regarding DNA synthesis effects from [@b1-ehp-117-1664]. Therefore, our analysis was restricted to rat precursor and potency data for the four compounds Wy-14,643, nafenopin, clofibrate, and DEHP and included both 1-week and 13-week data to separately address transient and sustained changes in DNA synthesis. Even for this small set of compounds, several limitations in the rat database were apparent. Because no single study provided comparative data for the precursor end points of interest, we used four separate reports. In the [@b99-ehp-117-1664] and [@b94-ehp-117-1664] studies of Wy-14,643 and clofibrate, respectively, administered doses were within 10% of the TD~50~. However, nafenopin data were available only at a single dose of 500 ppm ([@b56-ehp-117-1664]), which we linearly interpolated to the TD~50~. The highest administered dose of DEHP was 12,500 ppm ([@b15-ehp-117-1664]), a dose notably less than the TD~50~, and thus a lower limit based on the assumption of monotonicity with dose is shown. A further data limitation is that in the CPDB, the TD~50~ for only one of the four compounds, DEHP, incorporates data from studies administering more than one dose for 2 years.

The results shown in [Table 1](#t1-ehp-117-1664){ref-type="table"} indicate that potency for the occurrence of short-term *in vivo* markers of PPAR-α activation varies widely in magnitude and lacks any apparent correlation with carcinogenic potency. Such differences have been noted previously. Similar to the results presented in [Table 1](#t1-ehp-117-1664){ref-type="table"}, [@b60-ehp-117-1664] noted that although DEHP (12,000 ppm) and Wy-14,643 (1,000 ppm) induced a similar extent of hepatomegaly and peroxisome proliferation (measured either morphologically or biochemically) after 1 year, the frequency of hepatocelluar lesions was \> 100-fold higher in Wy-14,643--exposed relative to DEHP-exposed rats. In addition, a higher labeling index was reported for 12,500 ppm DEHP than the maximal level attained after 50--1,000 ppm Wy-14,643 ([@b15-ehp-117-1664]; [@b94-ehp-117-1664]; [@b99-ehp-117-1664]). We did not examine such differences in maximal responses in our analysis. We also do not present differences in response with dose and time seen among PPAR-α agonists, which are prominent enough to prevent displaying dose--response data on a common scale. For instance, labeling index, which is a measure of DNA synthesis, is increased in a dose-dependent manner at 1 week by clofibrate (1,500, 4,500, and 9,000 ppm) but is decreased compared with controls at 13 weeks at the two higher doses ([@b94-ehp-117-1664]). Together, these findings underscore the significant chemical-specific quantitative differences in these markers that limit their utility for predicting carcinogenic dose--response relationships.

To What Extent Are Humans Sensitive to PPAR-α Agonists?
=======================================================

Toxicodynamic differences across species, including in the absolute or allometrically scaled amount or activity of the receptor, may contribute to differences in sensitivity of response to PPAR-α agonists. Absolute levels of PPAR-α are generally thought to be lower in human compared with rodent liver. However, PPAR-α amount varies by an order of magnitude among individuals ([@b72-ehp-117-1664]; [@b97-ehp-117-1664]); for example, one of the six human samples examined expressed levels comparable to the mouse in one study ([@b100-ehp-117-1664]). The pattern of PPAR-α expression across tissues also differs across species ([@b63-ehp-117-1664]; [@b97-ehp-117-1664]); for example, human levels are higher in kidney and skeletal muscle than in liver, whereas the highest rodent levels are in liver and kidney. In addition, considerable inter-individual variation in PPAR-α structure and function among humans has been reported ([@b97-ehp-117-1664]), and polymorphisms have been shown to increase or decrease receptor levels and to modulate baseline lipid and apolipoprotein levels, atherosclerotic progression, and the presence of diabetes mellitus and insulin resistance ([@b21-ehp-117-1664], [@b20-ehp-117-1664]; [@b22-ehp-117-1664]; [@b50-ehp-117-1664]; [@b92-ehp-117-1664]; [@b95-ehp-117-1664]). An impact of PPAR-α polymorphisms on preexisting disease status and response to PPAR-α agonists is also suggested from bezafibrate \[2-(4-{2-\[(4-chlorophenyl)formamido\]ethyl}phenoxy)-2-methylpropanoic acid\] and gemfibrozil \[5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid\] trials ([@b50-ehp-117-1664]; [@b92-ehp-117-1664]).

The human PPAR-α is functional in *in vitro* transactivation assays and is responsive to a number of PPAR-α agonists (e.g., nafenopin, clofibrate, and WY-14,643) ([@b59-ehp-117-1664]; [@b68-ehp-117-1664]; [@b91-ehp-117-1664]). Compared with the mouse PPAR-α, human PPAR-α is suggested to be 10- to 20-fold less responsive to Wy-14,643 ([@b59-ehp-117-1664]; [@b68-ehp-117-1664]; [@b72-ehp-117-1664]). However, this magnitude of interspecies difference has not been demonstrated for other compounds. [@b43-ehp-117-1664] reported a 5-fold lower sensitivity to the DEHP metabolite MEHP of human compared with mouse PPAR-α (EC~50~ = 3.2 μM vs. 0.6 μM) in transfected COS-1 monkey kidney cells, but acknowledged that they could not quantify the relative amount of each receptor. Using a similar experimental paradigm, [@b104-ehp-117-1664] found an approximately 2-fold lower slope of the dose--response curve for activation of human compared with mouse PPAR-α for perfluorooctanoic acid and other perfluoroalkyl acids. For other compounds that activate PPAR-α, including TCA and DCA, little (\< 2-fold) or no species difference in receptor transactivation sensitivity was evident ([@b59-ehp-117-1664]). Some compounds appear to more efficiently activate human compared with rodent PPAR-α *in vitro*, as was demonstrated for the synthetic polyunsaturated fatty acid 5,8,11,14-eicosatetraynoic acid in transfected human liver cancer HepG2 cells ([@b68-ehp-117-1664]) and for perfluorobutane sulfonate in transfected COS-1 monkey kidney cells ([@b104-ehp-117-1664]).

Using adenovirus expression in PPAR-α--null mice, [@b110-ehp-117-1664] also found little (\< 2 fold) or no difference between the mouse and human receptor in terms of induction of *in vivo* markers of peroxisome proliferation. Wy-14,643, ciprofibrate, DEHP, and nafenopin enhanced mRNA and protein levels of peroxisomal genes regardless of whether the human or mouse PPAR-α was expressed ([@b110-ehp-117-1664]). Transgenic mice stably expressing human PPAR-α in the liver only ([@b8-ehp-117-1664]; [@b67-ehp-117-1664]) or in all tissues ([@b107-ehp-117-1664]) of PPAR-α--null mice exhibit increases in both DNA synthesis (with Wy-14,643) and hepatomegaly (with Wy-14,643 and fenofibrate \[propan-2-yl 2-{4-\[(4-chlorophenyl)carbonyl\]phenoxy}-2-methylpropanoate\]). However, these increases were much diminished from the response in wild-type mice and lacked statistical significance due largely to the small number of animals studied (*n* = 5--9). With regard to mouse liver tumor induction, Wy-14,643 (1,000 ppm) exposure for up to 44 weeks induced one liver adenoma in 20 PPAR-α-humanized mice, whereas none were seen in 10 untreated animals ([@b67-ehp-117-1664]); in comparison, Wy-14,643 (1,000 ppm) caused lethality in 5 of 10 wild-type mice at 38 weeks and tumors in the five surviving animals. These findings are suggestive of differential sensitivity of humanized mice to Wy-14,643. However, the accuracy of estimates of the extent of this difference is limited by the short exposure duration, the substantial mortality and morbidity in wild-type mice, the small number of animals studied, and potential differences in the interaction of the human receptor with mouse-specific coactivators and response elements.

Several key or associative events in the hypothesized MOA have been observed directly in some but not all primate studies ([@b40-ehp-117-1664]; [@b48-ehp-117-1664]; [@b55-ehp-117-1664]). Studies of cultured primary human hepatocytes have generally reported little or no proliferative response to peroxisome proliferators (for reviews, see [@b1-ehp-117-1664]; [@b75-ehp-117-1664]; [@b87-ehp-117-1664]). The culture conditions, including lack of cocultured nonparenchymal cells (e.g., Kupffer cells), may limit the *in vitro* hepatocyte proliferative response, as observed for other species (e.g., [@b73-ehp-117-1664]). The extent of peroxisome proliferation in human liver after exposure to fibrate drugs (e.g., with clofibrate, gemfibrozil, or fenofibrate) or dialysis treatment (possibly due to DEHP exposure) is reported to be generally less than the rodent response ([@b5-ehp-117-1664]; [@b17-ehp-117-1664]; [@b26-ehp-117-1664], [@b27-ehp-117-1664]; [@b28-ehp-117-1664]; [@b37-ehp-117-1664], [@b36-ehp-117-1664]). However, the ability to quantitatively characterize human sensitivity to this effect is limited (e.g., by the small number of subjects studied).

In sum, despite notable qualitative similarities, quantitative differences in receptor activation and the subsequent events in the hypothesized MOA are evident across species. The magnitude of these differences has been best characterized for Wy-14,643, to which rodents appear to have ≥ 10-fold greater sensitivity for response ([@b8-ehp-117-1664]; [@b59-ehp-117-1664]; [@b67-ehp-117-1664]; [@b68-ehp-117-1664]; [@b72-ehp-117-1664]; [@b110-ehp-117-1664]). Although more limited, studies of other compounds that activate PPAR-α suggest a smaller magnitude of difference in sensitivity for response across species than is seen for Wy-14,643 ([@b43-ehp-117-1664]; [@b59-ehp-117-1664]; [@b110-ehp-117-1664]). Considerable interindividual variation in PPAR-α amount, structure, and function has been reported among humans ([@b97-ehp-117-1664]), and some studies have suggested variability in human response to PPAR-α agonists ([@b50-ehp-117-1664]; [@b92-ehp-117-1664]). However, few studies have directly examined how these factors may affect sensitivity---as well as the potential for heterogeneity of response---to hepatocarcinogenesis induced by PPAR-α agonists in humans.

Do Human Epidemiologic Data on Fibrates Offer an Indirect Test of the PPAR-α Activation MOA Hypothesis?
=======================================================================================================

Human exposures to exogenous and endogenous PPAR-α agonists encompass a broad group of chemicals, including environmental contaminants known to activate the receptor, as well as a number of therapeutic agents whose molecular target is one or more receptors in the PPAR family. Indeed, fibrate drugs were developed using rodent models to treat hyperlipidemia in humans before the receptor was identified. These agents have varying degrees of affinity for PPAR-α ([@b90-ehp-117-1664]), and some have multiple mechanisms of action. Drugs that have PPAR-α agonist activity include fibrates or fibric acid derivatives (which are primarily PPAR-α agonists), bezafibrate (which also shows PPAR-γ activity), dual PPAR-α/γ agonists currently under development, the glitazones, and nonsteriod anti-inflammatory drugs (e.g., ibuprofen) ([@b89-ehp-117-1664]).

Some human data on PPAR-α agonist effects are available from fibrate clinical trials and population case--control studies of site-specific cancer ([@b3-ehp-117-1664], [@b4-ehp-117-1664]; [@b7-ehp-117-1664]; [@b9-ehp-117-1664], [@b10-ehp-117-1664], [@b11-ehp-117-1664]; [@b13-ehp-117-1664], [@b14-ehp-117-1664]; [@b16-ehp-117-1664]; [@b18-ehp-117-1664]; [@b23-ehp-117-1664]; [@b24-ehp-117-1664], [@b25-ehp-117-1664]; [@b44-ehp-117-1664]; [@b52-ehp-117-1664], [@b51-ehp-117-1664]; [@b62-ehp-117-1664]; [@b85-ehp-117-1664], [@b84-ehp-117-1664]; [@b96-ehp-117-1664]). These studies examined a range of human responses to PPAR-α agonists, which included atherosclerosis, cardiovascular disease, serum biomarkers of fatty acid metabolism, acute toxicity, and, more limitedly, organ-specific chronic toxicity, including cancer. However, examination of hepatotoxicity in the fibrate clinical trials has been limited to alterations in hepatic metabolic pathways and changes in liver enzymes as assessments of drug tolerance, because the primary focus of these trials was cardiovascular events.

Past reviews of the PPAR-α activation MOA hypothesis have generally focused on liver cancer response in two fibrate clinical trials, the Helsinki Heart Study ([@b24-ehp-117-1664]; [@b44-ehp-117-1664]; [@b96-ehp-117-1664]) and the World Health Organization's Cooperative Trial on Primary Prevention of Ischemic Heart Disease ([@b9-ehp-117-1664], [@b10-ehp-117-1664], [@b11-ehp-117-1664]), and have concluded that, although limited, those data did not provide evidence of an increased liver cancer risk from fibrate exposure ([@b1-ehp-117-1664]; [@b54-ehp-117-1664]). However, the available studies have low power to detect statistical differences in the risk of liver cancer; an estimated five or fewer liver cancer deaths would have been expected in these studies using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results database ([@b80-ehp-117-1664]). This low statistical power, in addition to the studies' exclusion or removal of subjects showing signs of liver (or other) toxicity from treatment, precludes a strong conclusion about the presence or lack of liver cancer risk. These studies and the other fibrate trials did not examine site-specific causes of mortality or morbidity and did not follow subjects for a sufficient period to adequately consider cancer latency; in addition, placebo subjects were offered fibrate therapy at the end of the clinical trials, making analyses after further follow-up difficult to interpret. For example, the three trials that did assess mortality after a follow-up period \> 10 years included liver cancers in a larger category of contiguous sites or in the category of all cancers, introducing disease misclassification and a downward bias for any site-specific treatment-related cancers ([@b7-ehp-117-1664]; [@b9-ehp-117-1664], [@b10-ehp-117-1664], [@b11-ehp-117-1664]; [@b44-ehp-117-1664]; [@b96-ehp-117-1664]). In voluntary postmarketing safety reports to the U.S. Food and Drug Administration (FDA), rates of liver adverse event reports for gemfibrozil and fenofibrate (2.6 and 6.9 per 1,000,000 prescriptions, respectively) were similar to those of statins ([@b41-ehp-117-1664]). However, an examination of liver cancer is precluded by the general underreporting of chronic toxicities to FDA, and the lack of specific FDA reporting requirements for cancer, even premarketing. Because of these inadequacies, the available epidemiologic data for fibrate drugs cannot inform conclusions about the relevance of PPAR-α activation to human cancer.

Conclusions
===========

As summarized in [Figure 1D](#f1-ehp-117-1664){ref-type="fig"}, the data reviewed and analyses presented in this article raise questions about whether the hypothesized PPAR-α activation MOA is either necessary or sufficient for rodent hepatocarcinogenesis. PPAR-α activation clearly plays a significant role in mouse liver tumor induction by some agonists, such as Wy-14,643. However, the recent study by [@b47-ehp-117-1664] suggests that DEHP can induce PPAR-α--independent tumors without any loss of potency. In addition, as demonstrated by [@b106-ehp-117-1664] in their transgenic model of PPAR-α activation in hepatocytes, a robust hepatocyte and peroxisome proliferative response is itself insufficient to cause tumorigenesis. Despite their potential limitations, these studies cast doubt on whether the proposed "key events" such as hepatocyte proliferation play a causal role in tumorigenesis or are merely correlated with cancer, as has been suggested for peroxisome proliferation in prior reviews (e.g., [@b54-ehp-117-1664]). The limited database of other studies that empirically challenge the necessity or sufficiency of the PPAR-α activation MOA in hepatocarcinogenesis per se also motivates a reexamination of whether this MOA hypothesis should be used as the basis for dismissing the human relevance of effects observed in laboratory animals. Of particular concern is whether human health risk assessment MOA conclusions should be based exclusively on evidence of PPAR-α activation and other key events in the hypothesized PPAR-α activation MOA, given that other modes, mechanisms, toxicity pathways and molecular targets may contribute to or be required for the observed adverse effects. Indeed, for most PPAR-α agonists, chemical-specific data to define the range of effects that may contribute to human carcinogenesis are insufficient. Similarly, the epidemiologic data are inadequate to inform conclusions of human relevance.

One possibility that deserves further consideration is that the main determinants of carcinogenicity may not be captured in the hypothesized PPAR-α activation MOA. A recent review ([@b87-ehp-117-1664]) addressed other mechanistic effects of DEHP and proposed that tumors arise from a combination of molecular signals and pathways, rather than from a single event such as PPAR-α activation. Indeed, the compounds that activate PPAR-α are pleiotropic and have been reported to exhibit a diversity of responses in addition to the hallmark effect of peroxisome proliferation, including genotoxicity (reviewed by [@b63-ehp-117-1664]), epigenetic alterations (e.g., hypomethylation) ([@b77-ehp-117-1664]), oxidative stress (reviewed in [@b71-ehp-117-1664]), and effects on other receptors (e.g., [@b33-ehp-117-1664]) and other organelles (e.g., mitochondria) within parenchymal cells ([@b58-ehp-117-1664]; [@b88-ehp-117-1664]; [@b109-ehp-117-1664]; [@b111-ehp-117-1664]). Importantly, several of these compounds (e.g., Wy-14,643, nafenopin, and DEHP) reportedly affect nonparenchymal liver cells that do not express PPAR-α ([@b73-ehp-117-1664]; [@b76-ehp-117-1664]; [@b81-ehp-117-1664], [@b82-ehp-117-1664]; [@b86-ehp-117-1664]) as well as other organ systems. Not all precursor, toxic, or carcinogenic effects rely solely on PPAR-α; for example, in PPAR-α--null mice, DEHP causes adverse testicular and renal effects at 24 weeks ([@b102-ehp-117-1664]) as well as hepatocarcinogenicity at 2 years ([@b47-ehp-117-1664]). Indeed, with regard to the hepatic, testicular, and pancreatic cancers associated with phthalate exposures, a report of the [@b70-ehp-117-1664] concluded that "there is evidence that these cancer types may be mediated by mechanisms independent of PPARα." Therefore, the adequacy of the scientific basis for the conclusion that PPAR-α agonists pose no carcinogenic risk to humans requires reexamination.

Perspectives and Future Directions
==================================

Our exploration of the hypothesized PPAR-α activation MOA highlights some of the critical challenges pertinent to the evaluation of mechanistic data and its use in decisions regarding the relative human sensitivity for biological effects observed in laboratory animals. Primary among these are differentiating causative from associative events in a proposed MOA, addressing multiple MOA hypotheses, and considering how Hill's considerations have been adopted to address these key questions. Alternatives to the use of Hill's considerations for assessing causality for toxicologic data have been discussed ([@b30-ehp-117-1664]; [@b35-ehp-117-1664]; [@b103-ehp-117-1664]). In addition, alternate conceptualizations of causal inference that allow for consideration of multiple causative factors may be instructive for MOA data evaluation. In particular, the sufficient-component cause model described originally by [@b83-ehp-117-1664] may provide useful theoretical and conceptual bases pertinent to evaluating MOA data and generating new MOA hypotheses. This model facilitates the conceptualization of hypotheses regarding multiple causes contributing to a single disease of interest and addresses such issues as multiple diseases arising from a single cause and multiple causes for a single disease with distinct models of susceptibility and biologic interactions, as well as background risk due to endogenous processes or other exposures. These "casual inference" methodologies may be useful in identifying the candidate key events, MOAs, or toxicity pathways that individually or together constitute the operant MOAs. Thereafter, direct experimentation is needed, and thus a critical aspect of MOA data evaluation is to consider the extent to which hypotheses have been challenged experimentally, according to the scientific method.

With regard to considerations of human sensitivity to any given MOA, our analyses support a change in focus from using quantitative data to make a "binary" determination of "relevant"/"not relevant" during hazard identification to a data-driven approach of using available quantitative data during dose--response estimation. This includes incorporating data-derived estimates of the degree of inter- as well as intraspecies differences in sensitivity to identified causal events in a hypothesized MOA during risk evaluation. The extent to which such quantitative approaches rely on a single MOA should be commensurate with the experimental support that the hypothesized MOA is the sole causative factor for carcinogenesis. These issues are especially important if the hypothesized MOA would be used as the basis for dismissing the human relevance of effects observed in laboratory animal models.

These considerations also highlight the need for a more robust database for compounds of environmental concern that activate PPAR-α, such as phthalates, perfluorinated acids, chlorinated solvents, and chloroacetic acids, either alone or in combinations relevant to human exposures. The extensive research focus on Wy-14,643 is particularly problematic, because *a*) it is typically administered at necrogenic doses well above those required for maximal responses; *b*) it is one of the few agonists that produce sustained, as opposed to only transient, enhancement of DNA synthesis in hepatocytes; *c*) unlike many other agonists, it preferentially activates rodent forms of PPAR-α (with humans exhibiting \~20-fold less sensitivity); and *d*) humans apparently have never been exposed to it, either in an experimental or clinical setting. Although it is assumed to be a prototype for the class, these considerations limit the general applicability of the research findings with Wy-14,643 to the diverse chemicals that activate PPAR-α. Rather than using Wy-14,643 and focusing exclusively on correlative effects in the hypothesized PPAR-α activation MOA in hepatocytes, experimental studies are needed that aim to elucidate and characterize the pleiotropic effects of PPAR-α agonists. Such research could broadly explore other mechanisms and identify the toxicity pathways responsible for effects that are known to be associated with human carcinogenesis. Based on this research, plausible MOA hypotheses for hepatocarcinogenesis induced by these environmental contaminants could be generated and ultimately tested using the scientific method.
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![(*A*) Hypothesized PPAR-α activation MOA as posited by [@b54-ehp-117-1664], with proposed "causal" events identified in green. (*B*) Is PPAR-α activation essential for DEHP carcinogenesis? Red outlines represent key events in the hypothesized PPAR-α activation MOA that were not induced by DEHP in PPAR-α--null mice despite the occurrence of tumors ([@b47-ehp-117-1664]; [@b102-ehp-117-1664]). Proposed causal events are shaded pink. These key events are therefore not necessary for tumors, suggesting PPAR-α--independent pathways for DEHP hepatocarcinogenesis. (*C*) Is PPAR-α activation alone sufficient for carcinogenesis? In the [@b106-ehp-117-1664] LAP-VP16PPAR-α transgenic model of constitutive PPAR-α activation in hepatocytes, the key events in the hypothesized PPAR-α activation MOA (green outlines), but not tumors, are induced at 11 months. Proposed causal events in the MOA are shaded light green. Wy-14,643 exposure in wild-type mice induces tumors at 11 months with comparable levels of hepatocyte proliferation and other proposed key events. This raises questions about whether PPAR-α activation and hepatocyte proliferation can alone cause tumors, and suggests that the sequence of key events in the hypothesized MOA is not solely sufficient to evoke carcinogenesis. (*D*) Revisiting the PPAR-α activation MOA. DEHP is hepatocarcinogenic in PPAR-α--null mice in which the red-outlined key events are absent ([@b47-ehp-117-1664]; [@b102-ehp-117-1664]), whereas, the green-outlined key events, but not tumors, are induced at 11 months in the LAP-VP16PPAR-α transgenic model ([@b106-ehp-117-1664]). Proposed causal events are shaded light green. Taken together, these findings support the view that the hypothesized PPAR-α activation MOA is neither necessary nor sufficient for hepatocarcinogenesis as a sole causative factor.](ehp-117-1664f1){#f1-ehp-117-1664}

![Incidences of hepatocellular adenomas (*A*) and hepatocellular adenomas and carcinomas (*B*) in mice exposed to DEHP. [@b47-ehp-117-1664] exposed PPAR-α--null (−/−) and wild-type (+/+) Sv129 mice for 22 months; [@b15-ehp-117-1664] exposed B6C3F1 wild-type (+/+) mice for up to 104 weeks. Data are presented as incidence ± SD assuming a binomial distribution for each group. All pairwise cross-study comparisons between like dose groups \[e.g., [@b47-ehp-117-1664] (−/−) 500 ppm vs. David et al. (+/+) 500 ppm\] were not significant by Fisher exact test. Because David et al. reported only adenomas and carcinomas, we excluded from analyses the cholangiocellular carcinoma reported by Ito et al. in DEHP-exposed PPAR-α--null mice. \*Significantly different from controls of the same genotype in the same study (Fisher exact test, *p* \< 0.05). \*\*Significant trend with dose in the study (Cochran Armitage test, *p* \< 0.05).](ehp-117-1664f2){#f2-ehp-117-1664}

###### 

Potency indicators for rat hepatocarcinogenicity and common short-term markers of PPAR-α activation for four PPAR-α agonists.

  Chemical     Tumor TD~50~ (ppm in diet)   Fold increase over control at tumor TD~50~                                     
  ------------ ---------------------------- -------------------------------------------- -------- ------- ------- -------- -------
  Wy-14,643    109                          1.8                                          12.0     13.0    2.6     6.8      39.0
  Nafenopin    275                          1.4                                          3.6      7.6     1.5     1.12     6.7
  Clofibrate   4,225                        1.4                                          4.4      4.2     1.4     0.95     3.7
  DEHP         17,900                       ≥1.4                                         ≥ 19.0   ≥ 3.6   ≥ 1.9   ≥ 1.25   ≥ 4.9

Abbreviations: LI, labeling index; PCO, cyanide-insensitive palmitoyl CoA oxidation; RLW, relative liver weight; TD~50~, daily dose inducing tumors in half of the mice that would otherwise have remained tumor-free. For ease of comparison with precursor effect studies, administered doses for the tumor TD~50~ values in the CPDB were back-converted to equivalent parts per million in diet using the formula of [@b29-ehp-117-1664]: TD~50~ (mg/kg-day) = TD~50~ (ppm in diet) × 0.04 (for male rats). Administered doses for precursor data on Wy-14,643 ([@b99-ehp-117-1664]) and clofibrate ([@b94-ehp-117-1664]) were within 10% of the TD~50~. Because nafenopin precursor data were available only at 0 and 500 ppm ([@b56-ehp-117-1664]), these doses were linearly interpolated to the TD~50~. Because the highest administered dose of DEHP in precursor effect studies was 12,500 ppm ([@b15-ehp-117-1664]), a lower limit is shown, based on the assumption of monotonicity with dose.

###### 

Potency indicators for mouse hepatocarcinogenicity and *in vitro* transactivation of mouse PPAR-α for four PPAR-α agonists.

  Hepatocarcinogen   Carcinogenic potency indicator (TD~50~; mg/kg-day)   Transactivation potency indicators (μM)   
  ------------------ ---------------------------------------------------- ----------------------------------------- -------
  Wy-14,643          \< 10.8                                              0.63                                      \~0.4
  DCA                119.0                                                \~800                                     \~600
  TCA                584.0                                                \~500                                     \~300
  DEHP/MEHP          700.0                                                \~0.7                                     \~0.7

The "\<" symbol denotes an upper limit due to maximal response. A "\~" symbol indicates that the transactivation potency was approximated (to one significant figure) from figures or tables in [@b59-ehp-117-1664].
